Yogesh N V Reddy1, Masaru Obokata1, Aaron D Jones2, Gregory D Lewis3, Sanjiv J Shah4, Omar F Abouezzedine1, Marat Fudim5, Brooke Alhanti2, Lynne W Stevenson6, Margaret M Redfield1, Barry A Borlaug7. 1. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. 2. Duke Clinical Research Institute, Durham, North Carolina. 3. Division of Cardiology, Massachusetts General Hospital, Boston, Massachusetts. 4. Division of Cardiology, Northwestern University; Chicago, Illinois. 5. Division of Cardiology, Duke University, Durham, North Carolina. 6. Division of Cardiology, Vanderbilt University, Nashville, Tennesee. 7. Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: borlaug.barry@mayo.edu.
Abstract
BACKGROUND: Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Some patients develop elevated filling pressures exclusively during exercise and never require hospitalization, whereas others periodically develop congestion that requires inpatient treatment. The features differentiating these cohorts are unclear. METHODS: We performed a secondary analysis of 7 National Institutes of Health-sponsored multicenter trials of HFpEF (EF ≥ 50%, N = 727). Patients were stratified by history of hospitalization because of HF, comparing patients never hospitalized (HFpEFNH) to those with a prior hospitalization (HFpEFPH). Currently hospitalized (HFpEFCH) patients were included to fill the spectrum. Clinical characteristics, cardiac structure, biomarkers, quality of life, functional capacity, activity levels, and outcomes were compared. RESULTS: As expected, HFpEFCH (n = 338) displayed the greatest severity of congestion, as assessed by N-terminal pro B-type natriuretic peptide levels, edema and orthopnea. As compared to HFpEFNH (n = 109), HFpEFPH (n = 280) displayed greater comorbidity burden, with more lung disease, renal dysfunction and anemia, along with lower activity levels (accelerometry), poorer exercise capacity (6-minute walk distance and peak exercise capacity), and more orthopnea. Patients with current or prior hospitalization displayed higher rates of future HF hospitalization, but quality of life was similarly impaired in all patients with HFpEF, regardless of hospitalization history. CONCLUSIONS: A greater burden of noncardiac organ dysfunction, sedentariness, functional impairment, and higher event rates distinguish patients with HFpEF and prior HF hospitalization from those never hospitalized. Despite lower event rates, quality of life is severely and similarly limited in patients with no history of hospitalization. These data suggest that the 2 clinical profiles of HFpEF may require different treatment strategies.
BACKGROUND:Heart failure (HF) with preserved ejection fraction (HFpEF) is a heterogeneous syndrome. Some patients develop elevated filling pressures exclusively during exercise and never require hospitalization, whereas others periodically develop congestion that requires inpatient treatment. The features differentiating these cohorts are unclear. METHODS: We performed a secondary analysis of 7 National Institutes of Health-sponsored multicenter trials of HFpEF (EF ≥ 50%, N = 727). Patients were stratified by history of hospitalization because of HF, comparing patients never hospitalized (HFpEFNH) to those with a prior hospitalization (HFpEFPH). Currently hospitalized (HFpEFCH) patients were included to fill the spectrum. Clinical characteristics, cardiac structure, biomarkers, quality of life, functional capacity, activity levels, and outcomes were compared. RESULTS: As expected, HFpEFCH (n = 338) displayed the greatest severity of congestion, as assessed by N-terminal pro B-type natriuretic peptide levels, edema and orthopnea. As compared to HFpEFNH (n = 109), HFpEFPH (n = 280) displayed greater comorbidity burden, with more lung disease, renal dysfunction and anemia, along with lower activity levels (accelerometry), poorer exercise capacity (6-minute walk distance and peak exercise capacity), and more orthopnea. Patients with current or prior hospitalization displayed higher rates of future HF hospitalization, but quality of life was similarly impaired in all patients with HFpEF, regardless of hospitalization history. CONCLUSIONS: A greater burden of noncardiac organ dysfunction, sedentariness, functional impairment, and higher event rates distinguish patients with HFpEF and prior HF hospitalization from those never hospitalized. Despite lower event rates, quality of life is severely and similarly limited in patients with no history of hospitalization. These data suggest that the 2 clinical profiles of HFpEF may require different treatment strategies.
Authors: Sameer Ather; Wenyaw Chan; Biykem Bozkurt; David Aguilar; Kumudha Ramasubbu; Amit A Zachariah; Xander H T Wehrens; Anita Deswal Journal: J Am Coll Cardiol Date: 2012-03-13 Impact factor: 24.094
Authors: Jennifer E Ho; Emily K Zern; Luke Wooster; Cole S Bailey; Thomas Cunningham; Aaron S Eisman; Kathryn M Hardin; Giovanna A Zampierollo; Petr Jarolim; Paul P Pappagianopoulos; Rajeev Malhotra; Matthew Nayor; Gregory D Lewis Journal: Circulation Date: 2019-05-28 Impact factor: 29.690
Authors: Javed Butler; Kevin J Anstrom; G Michael Felker; Michael M Givertz; Andreas P Kalogeropoulos; Marvin A Konstam; Douglas L Mann; Kenneth B Margulies; Steven E McNulty; Robert J Mentz; Margaret M Redfield; W H Wilson Tang; David J Whellan; Monica Shah; Patrice Desvigne-Nickens; Adrian F Hernandez; Eugene Braunwald Journal: JAMA Cardiol Date: 2017-09-01 Impact factor: 14.676
Authors: Ambarish Pandey; Kershaw V Patel; Colby Ayers; W H Wilson Tang; James C Fang; Mark H Drazner; Jarett Berry; Justin L Grodin Journal: Eur J Heart Fail Date: 2019-04-01 Impact factor: 15.534
Authors: Peter E Carson; Inder S Anand; Sithu Win; Thomas Rector; Markus Haass; Jose Lopez-Sendon; Alan Miller; John R Teerlink; Michel White; Robert S McKelvie; Michel Komajda; Michael R Zile; John J McMurray; Barry Massie Journal: JACC Heart Fail Date: 2015-05-14 Impact factor: 12.035
Authors: Yogesh N V Reddy; Masaru Obokata; Frederik H Verbrugge; Grace Lin; Barry A Borlaug Journal: J Am Coll Cardiol Date: 2020-09-01 Impact factor: 24.094
Authors: Natalie A Bello; Brian Claggett; Akshay S Desai; John J V McMurray; Christopher B Granger; Salim Yusuf; Karl Swedberg; Marc A Pfeffer; Scott D Solomon Journal: Circ Heart Fail Date: 2014-05-29 Impact factor: 8.790
Authors: Margaret M Redfield; Kevin J Anstrom; James A Levine; Gabe A Koepp; Barry A Borlaug; Horng H Chen; Martin M LeWinter; Susan M Joseph; Sanjiv J Shah; Marc J Semigran; G Michael Felker; Robert T Cole; Gordon R Reeves; Ryan J Tedford; W H Wilson Tang; Steven E McNulty; Eric J Velazquez; Monica R Shah; Eugene Braunwald Journal: N Engl J Med Date: 2015-11-08 Impact factor: 91.245
Authors: Vanessa Frodermann; David Rohde; Gabriel Courties; Nicolas Severe; Maximilian J Schloss; Hajera Amatullah; Cameron S McAlpine; Sebastian Cremer; Friedrich F Hoyer; Fei Ji; Ian D van Koeverden; Fanny Herisson; Lisa Honold; Gustavo Santos Masson; Shuang Zhang; Jana Grune; Yoshiko Iwamoto; Stephen P Schmidt; Gregory R Wojtkiewicz; I-Hsiu Lee; Karin Gustafsson; Gerard Pasterkamp; Saskia C A de Jager; Ruslan I Sadreyev; Jean MacFadyen; Peter Libby; Paul Ridker; David T Scadden; Kamila Naxerova; Kate L Jeffrey; Filip K Swirski; Matthias Nahrendorf Journal: Nat Med Date: 2019-11-07 Impact factor: 53.440